News
June 26, 2020
Researchers designed a risk prediction score for early severe infection in patients with multiple myeloma regardless of transplant eligibility.
Podcast
June 26, 2020
Chadi checks in with Graham Collins, David Steensma, and Vincent Rajkumar to discuss the most prevalent and noteworthy clinical research from the EHA meeting for Hodgkin lymphoma, MDS and AML, multiple myeloma, and DLBCL.
News
June 25, 2020
A retrospective, population-based study compared the long-term outcomes of patients with MCL who were treated with four different immunochemotherapy regimens.
News
June 22, 2020
In patients with relapsed or refractory multiple myeloma and soft -tissue plasmacytomas, an isatuximab-based regimen may significantly improve PFS and ORR with a manageable safety profile, according to new research.
News
June 18, 2020
Researchers demonstrated improved health-related quality of life for patients with heavily pretreated or renally impaired relapsed/refractory multiple myeloma after treatment with a combination regimen.
News
June 18, 2020
Recent research suggests cytologic and genetic alteration factors that are significant drivers of progressive disease in mantle cell lymphoma.
News
June 17, 2020
Researchers presenting at the European Hematology Association Virtual Meeting described the cumulative incidence of secondary malignancies resulting from treatment of Hodgkin lymphoma as well as risk factors for such malignancies.
News
June 16, 2020
Patients with relapsed or refractory non-GCB DLBCL and high PAX5 expression or CD79B mutation have a higher likelihood of responding to BTK inhibitor therapy, according to a recent study.
News
June 15, 2020
A study presented at the European Hematology Association Virtual Meeting showed that BTK inhibitor therapy is effective for patients with heavily pretreated, high-risk CLL, including those with prior Richter transformation in remission.